Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.